ClinicalTrials.gg

Program

Prednisolone

Also written as “Desloratadine + Prednisolone”, “prednisolone” and “Desloratadine , Prednisolone”.

Its studies are mostly in Prostatic Neoplasms · Arthritis, Rheumatoid · Rhinitis, Allergic · Asthma · Pulmonary Disease, Chronic Obstructive, led by 13 companies.

Furthest: phase 4, since Mar 11, 201026 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline50 open or runningphase 3since Mar 11, 2010Aug 24, 2005none ahead
Sanofi50 open or runningphase 4since Feb 26, 2014Jul 9, 2007none ahead
EMS40 open or runningphase 3since Sep 5, 2011Sep 5, 2011none ahead
Astellas Pharma32 open or runningphase 2since May 27, 2025Jun 26, 2024Oct 31, 2027phase 2 · NCT07052929
adapt-produtos-oftalmolo-gicos-ltda10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
Bausch Health Companies10 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Biogen10 open or runningphase 4since Jul 29, 2010Jul 29, 2010none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since Jan 3, 2019Jan 3, 2019none ahead
Eurofarma Laboratorios10 open or runningphase 3since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medical10 open or runningphase 3since Nov 7, 2012Nov 7, 2012none ahead
Hoffmann-La Roche10 open or runningphase 2since Sep 6, 2013Sep 6, 2013none ahead
Ultragenyx Pharmaceutical10 open or runningphase 3since Jul 14, 2021Jul 14, 2021none ahead
zalicus10 open or runningphase 2since Jun 7, 2011Jun 7, 2011none ahead

Also a collaborator on its studies: elan-pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Aug 24, 2005.

  1. Sep 5, 2011EMS's first study: phase 3 study in EczemaNew to EMSEMS · NCT01429701 · 76 enrolled
  2. Feb 6, 20122 phase 3 studiesEMS · NCT01529242, NCT01529229
  3. Oct 31, 2012Phase 3 study in Rhinitis, AllergicEMS · NCT01720485 · 234 enrolled · Brazil
  4. Nov 7, 2012Hamad Medical's first study: phase 3 study in Arthritis, RheumatoidNew to Hamad MedicalHamad Medical · NCT01724268 · 80 enrolled · Qatar
  5. Sep 6, 2013Hoffmann-La Roche's first study: phase 2 study in AsthmaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01948401 · 54 enrolled · United Kingdom
  6. Feb 26, 2014Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02074137 · 10 enrolled · India
  7. May 8, 2015Phase 4 study in Prostatic NeoplasmsSanofi · NCT02441894 · 21 enrolled · Japan
  8. Nov 2, 2017Phase 3 study in Multiple SclerosisSanofi · NCT03368664 · 16 enrolled · France, Italy, Poland and more
  9. Jan 3, 2019Chong Kun Dang Pharmaceutical's first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
  10. Jul 14, 2021Ultragenyx Pharmaceutical's first study: phase 3 study in Hepatorenal form of glycogen storage diseaseNew to Ultragenyx PharmaceuticalUltragenyx Pharmaceutical · NCT05139316 · 52 enrolled · United States, Brazil, Canada and more
  11. Dec 13, 2021Eurofarma Laboratorios's first study: phase 3 study in Rhinitis, AllergicNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05214911 · 262 enrolled · Brazil
  12. Jun 26, 2024Astellas Pharma's first study: phase 1 study in Friedreich AtaxiaNew to Astellas PharmaAstellas Pharma · NCT06483802
  13. May 27, 2025Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154 · 218 planned · United States, China, France and more
  14. Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
  2. May 31, 2032Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07052929Myopathies, Structural, Congenital · United States, Canada2RecruitingAstellas PharmaOct 31, 20279
NCT07005154Prostatic Neoplasms · United States, China, France and more2RecruitingAstellas PharmaMay 31, 2032218
NCT06483802Friedreich Ataxia1WithdrawnAstellas PharmaOct 22, 20250
NCT05214911Rhinitis, Allergic · Brazil3CompletedEurofarma LaboratoriosMar 23, 2025262
NCT05139316Hepatorenal form of glycogen storage disease · United States, Brazil, Canada and more3CompletedUltragenyx PharmaceuticalFeb 20, 202452
NCT03794492Kidney Transplant · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJul 22, 2022169
NCT03368664Multiple Sclerosis · France, Italy, Poland and more3TerminatedSanofiMay 4, 202116
NCT02441894Prostatic Neoplasms · Japan4CompletedSanofiFeb 201621
NCT02074137Prostate Cancer Metastatic · India4CompletedSanofiMar 201610
NCT01948401Asthma · United Kingdom2CompletedHoffmann-La RocheApr 201454
NCT01724268Arthritis, Rheumatoid · Qatar3UNKNOWNHamad MedicalMay 201480
NCT01720485Rhinitis, Allergic · Brazil3UNKNOWNEMSDec 2013234
NCT01529242Cutaneous Hypersensitivity · Brazil3TerminatedEMSAug 201617
NCT01529229Rhinitis, Allergic3CompletedEMSOct 2014210
NCT01429701Eczema3CompletedEMSJun 201276
NCT01369745Arthritis, Rheumatoid · United States2CompletedzalicusAug 2012294
NCT01603030Eye Infections · Brazil3UNKNOWNadapt-produtos-oftalmolo-gicos-ltdaAug 201266
NCT01324583Prostatic Neoplasms · Japan1CompletedSanofiNov 201448
NCT01211665Immune Reconstitution Inflammatory Syndrome · United States, Germany4TerminatedBiogenFeb 20123
NCT01086410Asthma · United States, Germany, Poland3CompletedGlaxoSmithKlineSep 2010185
NCT00498797Prostatic Neoplasms · Brazil, Germany, Hungary and more2CompletedSanofiJul 200786
NCT00384306Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedGlaxoSmithKlineJan 20069
NCT00379730Pulmonary Disease, Chronic Obstructive · Argentina, Chile, New Zealand and more1CompletedGlaxoSmithKline90
NCT00327197Asthma · United Kingdom1TerminatedGlaxoSmithKlineJun 6, 201147
NCT00198523Eye Infections · United States3CompletedBausch Health CompaniesOct 2005132
NCT00134693Arthritis, Rheumatoid · Australia, France, Germany and more2CompletedGlaxoSmithKlineAug 3, 200677

How it is read

Names in the registry

  • “Prednisolone”, 17 entries
  • “Desloratadine + Prednisolone”, 3 entries
  • “prednisolone”, 3 entries
  • “Desloratadine , Prednisolone”, 1 entry
  • “Oral prednisolone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.